Following a positive recommendation from Europe’s Committee for Medicinal Products for Human Use (CHMP), the European Commission on Monday 19th December formally approved Atara Biotherapeutics ...
Story March 4 - Atara Biotherapeutics: While the biotech navigates the fallout from the FDA’s move to halt trials of its allogeneic T-cell immunotherapy Ebvallo and a CAR-T candidate ...
Stifel Nicolaus analyst Benjamin Burnett maintained a Hold rating on Atara Biotherapeutics (ATRA – Research Report) yesterday and set a price ...
TD Cowen analyst Phil Nadeau maintained a Buy rating on Atara Biotherapeutics (ATRA – Research Report) yesterday. The company’s shares closed ...
Revenue: US$128.9m (up by US$120.4m from FY 2023). Net loss: US$85.4m (loss narrowed by 69% from FY 2023). US$11.41 loss per share (improved from US$65.18 loss in FY 2023). Revenue exceeded ...
6d
TipRanks on MSNAtara Biotherapeutics Faces Potential Liquidation: Strategic Decisions Crucial for Investor OutcomesAtara Biotherapeutics Inc (ATRA) has disclosed a new risk, in the Corporate Activity and Growth category. Atara Biotherapeutics Inc faces ...
After hours: March 13 at 5:39:14 PM EDT Loading Chart for ATRA ...
With cutting-edge technology, a robust regulatory framework, and a highly skilled team, BTCF is committed to driving innovation in cell therapy research and clinical translation, helping to bring next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results